CALC — CalciMedica, Inc.

Is CALC overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

CalciMedica, Inc. (CALC) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.19. The rating moved from Strong Oversold to Oversold on November 14, 2026.

See all oversold Healthcare stocks →

AI analysis

CalciMedica, Inc. exhibits typical small-cap biotech characteristics: value is highly event-driven and visibility is constrained by limited public filings and coverage. Near-term performance will be driven by cash runway, financing choices, and any clinical/regulatory or partnership announcements. Sector flows currently favor large-cap pharma and defensive healthcare, which may limit demand for microcap development names. Key risks include dilution, clinical setbacks, and low liquidity that can amplify moves. Investors should monitor upcoming milestone dates, cash-burn trends, and any non-dilutive financing or licensing activity for changes to the outlook.

Key factors

  • Very limited publicly available recent filings and social/research coverage, increasing information asymmetry
  • Small-cap/biotech profile with outcome-driven valuation tied to clinical or regulatory milestones
  • Broader sector flows favor large-cap pharma and defensive healthcare, reducing near-term investor appetite for microcap biotech risk
  • Convertible-debt and financing environment in mid/small biotech raises probability of dilution or expensive financing needs
  • Potential near-term catalysts include clinical data readouts, partnering/licensing announcements, or non-dilutive financing
  • Low liquidity and tight float can amplify price moves on news, both positive and negative

Risks

  • Cash runway uncertainty and need for equity or dilutive financing absent clear revenue streams
  • Clinical or regulatory setbacks for development-stage programs that could materially reduce enterprise value
  • Limited visibility from a lack of recent EDGAR/reporting detail and scarce sell-side coverage
  • Competitive landscape and larger-cap pharma entrants that can outspend on development and commercialization
  • Low trading liquidity leading to heightened volatility and difficulty executing large trades
  • Adverse macro/sector rotation away from small-cap biotech in a risk-off environment

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CALC — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.